New Science

CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.

The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.

Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”

Technical challenges and lackluster investor sentiment about the near-term commercial potential of cell and gene therapies in neurological disorders may be holding the field back.

Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity. 

Iovance Biotherapeutics' Amtagvi (lifileucel) received approval from the US FDA in February, marking a truly pivotal milestone in the field of solid tumor therapy for certain adult patients with unresectable or metastatic melanoma. As the first approved tumor infiltrating lymphocyte (TIL) therapy, it is set to expedite the regulatory pathway for next-generation products.

Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.

Non-executive chair Peter Bains and Owain Millington, vice president of immunology and head of preclinical, discuss ILC Therapeutics’ platform technology, financing plans as well as the pros and cons of running a startup biotech in the UK.

Quantum computing is both mysterious and prone to hype, but the reality of a quantum era is approaching and the benefits for biopharma could be enormous. Prepare ahead of time to gain a first mover advantage, say the experts. 

There is growing interest in rare neurological diseases, but barriers to efficient drug development exist. Bruce Leuchter, CEO of Neurvati Neurosciences, spoke to In Vivo about some of the hurdles in clinical-stage asset development and solutions to smooth that path. 

There is an opportunity in Austria: the country is teeming with advanced research and strong talent, but much of it remains commercially untapped. 

CUTISS co-founder and CEO Daniela Marino shares insights with In Vivo about the future of regenerative medicine and the ongoing development of denovoSkin, a next-generation human skin graft technology.

Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.

Serna Bio is using machine learning and RNA biology to create a platform for the discovery of small molecule modulators of RNA. The startup will seek fresh funding in 2024 and is on the hunt for creative biopharma partnerships.